Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 236,675,987 papers from all fields of science
Search
Sign In
Create Free Account
suvorexant
Known as:
[(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
, [(7R)-4-(5-Chlor-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanon
, methanone, ((7R)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-methyl-1H-1,4-diazepin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)-
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
8 relations
Broader (4)
Azepines
Orexin Receptor Antagonists
Sleep Aids, Pharmaceutical
Triazoles
Narrower (2)
Belsomra
MK 4305
Orexin Receptor Antagonists [MoA]
suvorexant 15 MG Oral Tablet [Belsomra]
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Clinical Experience with a Dual Orexin Receptor Antagonist, Suvorexant (Belsomra) in Japan
H. Ono
,
T. Kanbayashi
,
+7 authors
T. Shimizu
2018
Corpus ID: 149493542
Objective: Suvorexant, a dual orexin receptor antagonist, was launched as a hypnotic in Japan in 2014. We summarize our…
Expand
Review
2017
Review
2017
Suvorexant as an Adjunctive Treatment for Insomnia Prior toDiscontinuation of Benzodiazepines: Prevention of Withdrawal Syndromeand Rebound Insomnia
S. Yokoyama
,
T. Tsuneoka
,
+6 authors
and Akira Iwanami
2017
Corpus ID: 27995613
Objective: To examine whether concurrent use of benzodiazepines (BZDs) affects continuation rates for suvorexant. Background: A…
Expand
Review
2017
Review
2017
WHO downgrades Tamiflu Suvorexant : A hypnotic causing cataplexy Insomnia , Sleep Duration , Harm of hypnotics PPI causes Pneumonia
2017
Corpus ID: 3890483
Editorial WHO downgraded oseltamivir (Tamiflu) New Products Hypnotic (sleeping pill), suvorexant (brand name Belsomra) A…
Expand
Review
2017
Review
2017
Physical activity and quality of life in long-term hospitalized patients with severe mental illness : a cross-sectional study
Ajeet B Singh
2017
Corpus ID: 4186509
Welcome to issue 43 of Psychiatry Research Review. Very interesting findings are reported by one of the papers in this issue…
Expand
Review
2016
Review
2016
Is Suvorexant (Belsomra) Effective in Reducing Wakefulness after Sleep Onset in Healthy Patients Diagnosed with Insomnia
D. Hart
2016
Corpus ID: 59264129
OBJECTIVE: The objective of this selective EBM review is to determine if Suvorexant (Belsomra) is effective in reducing…
Expand
2016
2016
Induced next-day somnolence in an elderly patient taking suvorexant concomitantly with diltiazem.
Atsuko Shihyakugari
,
Satoko Hori
,
A. Miki
,
Y. Sawada
International journal of clinical pharmacology…
2016
Corpus ID: 34562921
OBJECTIVE To present the first case of induced next-day somnolence in a patient taking suvorexant concomitantly with diltiazem…
Expand
2015
2015
Mitral valve replacement with successful removal of very large left atrial organised clot [300gms] secondary to coronary cameral fistula
S. Nagre
,
Manisha Suraj Nagre
2015
Corpus ID: 217932033
Left atrial clot is common in mitral valve disease. They are even more commonly seen after an episode of atrial fibrillation…
Expand
2015
2015
Novel routes of synthesis for preparation of suvorexant
R·巴尔特
,
K·霍弗尔-普兰茨
,
F·里希特
,
G·威德施文特尔
2015
Corpus ID: 139149289
The present invention relates to a process for the preparation of a compound of formula (A), Further, the present invention…
Expand
2015
2015
Synthetic method for intermediate of suvorexant as anti-insomnia medicament
葛德培
,
吴其华
,
刘涛
2015
Corpus ID: 104326367
The invention relates to a synthetic method for an intermediate of suvorexant as an anti-insomnia medicament. The synthetic…
Expand
2013
2013
FDA panel OKs Merck insomnia agent suvorexant at lower doses
F. Staff
2013
Corpus ID: 71005576
Soon after FDA expressed concerns over the higher dosages and safety profile, including daytime drowsiness, of the proposed sleep…
Expand